thalidomide nh ch2 cooh

2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino}acetic acid (trifluoroacetic acid) is mainly used in compounds Synthesis.

Thalidomide-NH-CH2-COOH ((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)glycine) is a synthesized E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker.

Thalidomide-CH2CONH-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-NH-C2-PEG3-OH (H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]amino]-) is an E3 ligase ligand-linker conjugate.

Thalidomide-NH-PEG1-NH2 hydrochloride (4-[(2-(2-Aminoethoxy)ethyl)amino]-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione HCl) is a synthetic E3 ligase ligand-linker conjugate that incorporates the Thalidomide-based cereblon ligand and a linker[1].

Thalidomide-CH2CONH-C2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and linker used in PROTAC technology.

Hydroxy-PEG4-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG4-(CH2)2-Boc can also be used in the synthesis of PROTAC.

Selective bradykinin B2 receptor agonist that is resistant to carboxypeptidase cleavage. 5-fold more potent and exhibits a more prolonged duration of action than bradykinin in vivo.

Thalidomide-NH-C4-NH-Boc is a synthesized conjugate used in PROTAC technology, combining a Thalidomide-based cereblon ligand with a linker.

Thalidomide-NH-(CH2)2-NH2 TFA is an alkyl-modified derivative of Thalidomide serving as a Cereblon ligand to recruit CRBN proteins and a pivotal intermediate in the synthesis of CRBN-based PROTAC molecules for the targeted small molecule PROTACs aimed at SHP2 protein.

HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a peptide-cleavable agent-linker conjugate utilized in antibody-drug conjugates (ADCs), with the DM denoting the maytansinoid component [1].

Pomalidomide-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

CC-885-CH2-PEG1-NH-CH3 is a neoDegrader compound employed for the production of Antibody neoDegrader Conjugate (AnDC) during synthesis.

Biotinyl-NH-PEG3-C3-amido-C3-COOH (DIPEA) is a polyethylene glycol (PEG)-based proteolysis targeting chimera (PROTAC) linker, utilized for synthesizing PROTACs.

Fmoc-Gly-NH-CH2-O-CH2COOH is an ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs) [1].

Thalidomide-O-COOH (Cereblon ligand 3) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. It can be connected to the ligand for protein by a linker to form PROTACs.

MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC linker commonly employed in ADC synthesis. This cleavable linker plays a fundamental role in the conjugation process of antibody-drug conjugates (ADCs).

Thalidomide-O-C8-COOH, also known as Cereblon ligand 3, is a Thalidomide-derived compound that serves as a Cereblon (CRBN) ligand for the targeted recruitment of CRBN protein. It can be coupled via a linker to another ligand to create proteolysis-targeting chimeras (PROTACs)[1].

Thalidomide-5-NH2-CH2-COOH (compound 114) is a selective inhibitor of the protomyosin receptor kinase. It is a ligand for E3 ligase and has potential for studying one or more diseases.

Thalidomide-O-C6-COOH is a synthetic conjugate comprising an E3 ligase ligand-linker, which combines the Thalidomide derived cereblon ligand with a PROTAC technology linker.

Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC linker utilized in the synthesis of drug-linker conjugates specific to ADCs, notably for creating Deruxtecan, a potent drug-linker conjugate [1].

Thalidomide-NH-C4-NH2 TFA (compound 29c) is a conjugate consisting of an E3 ligase ligand-linker, incorporating the Thalidomide-based cereblon ligand and a linker moiety. This compound, Thalidomide-NH-C4-NH2 TFA, is utilized as a component in PROTAC BRD2/BRD4 degrader-1, which is a highly potent and selective degrader targeting BET proteins BRD4 and BRD2[1].

(D(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin, serving as an oxytocin receptor antagonist, effectively nullifies the augmentation of inhibitory postsynaptic currents in CA1 pyramidal neurons by oxytocin [1].

Functionalized cereblon ligand for PROTAC research and development; incorporates an E3 ligase ligand plus an alkylC5 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Pomalidomide - linker 4 PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.

Thalidomide-NH-C8-NH2 hydrochloride is a synthetic compound, which functions as an E3 ligase ligand-linker conjugate. It consists of a cereblon ligand derived from Thalidomide, along with a linker commonly used in PROTAC technology.

Thalidomide-NH-C8-NH2 is a synthetic conjugate of an E3 ligase ligand-linker, which combines a cereblon ligand based on Thalidomide with a specific linker utilized in PROTAC technology.

Thalidomide-NH-C10-NH2 hydrochloride, a thalidomide-derived cereblon ligand, facilitates CRBN protein recruitment and, when conjugated with a linker, forms PROTACs [1].

Thalidomide-5-NH-PEG1-NH2 hydrochloride is a Thalidomide-based cereblon ligand designed for CRBN protein recruitment. It facilitates the formation of PROTAC molecules by linking to target protein ligands, such as THAL-SNS-032, via a connector.

Thalidomide-NH-PEG7 is a synthesized conjugate of an E3 ligase ligand and linker designed for use in antibody-drug conjugates (ADCs). This compound can be coupled to a protein ligand via a linker to create PROTAC iRucaparib-AP6, an extremely selective degrader of PARP1[1].

Thalidomide-5-CH2-NH2 (hydrochloride) is a derivative of Thalidomide that serves as a cereblon ligand, specifically utilized for the recruitment of CRBN protein. This compound, Thalidomide-5-CH2-NH2 (hydrochloride), can be connected to a protein ligand through a linker, resulting in the formation of PROTACs.

Thalidomide-NH-PEG4-Ms is a conjugate that consists of a cereblon ligand based on Thalidomide and a linker molecule, which serves as a ligand-linker moiety for E3 ligase. This conjugate is specifically designed as a degrader for PROTAC BCL-XL, known as XZ739.

Thalidomide-NH-C10-COOH (compound 6b) is a synthetic E3 ligase ligand-linker conjugate. This compound combines the Thalidomide-based von Hippel-Lindau (VHL) ligand with a linker commonly employed in PROTAC technology. [1]

Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a chemically synthesized compound, designed as an E3 ligase ligand-linker conjugate, integrating the cereblon ligand derived from Pomalidomide and a linker employed in PROTAC technology. This compound serves to facilitate targeted protein degradation through the modulation of E3 ligase activity, enabling the selective elimination of specific proteins of interest.

Thalidomide-5-NH-PEG3-NH2 hydrochloride is a cereblon ligand based on Thalidomide that targets CRBN proteins. It utilizes a linker to attach to a target protein ligand, facilitating the formation of a PROTAC molecule, such as THAL-SNS-032.

Difluorocyclooctyne-CH2-COOH, a difluorinated cyclooctyne (DIFO) analogue, facilitates imaging of glycans on live cells by rapidly reacting with azides without requiring copper catalysis. This characteristic makes it an effective tool for bioorthogonal conjugation in live cell studies.

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized conjugate compound known as an E3 ligase ligand-linker. It incorporates a cereblon ligand based on Thalidomide and a 3-unit PEG linker. This compound is specifically designed for use in PROTAC technology applications.

Thalidomide-NH-PEG8-Ts is a chemically synthesized conjugate consisting of a Thalidomide-based cereblon ligand and an 8-unit PEG linker. This conjugate serves as an E3 ligase ligand-linker in PROTAC technology applications, including the degradation of IDO1 by a PROTAC degrader.

Thalidomide-NH-PEG3-COOH is a conjugate of the E3 ligase ligand-linker synthesized compound, which integrates a cereblon ligand based on Thalidomide and a linker employed in PROTAC technology.

Thalidomide-C2-amido-C2-COOH is a compound that includes a CRBN ligand for the E3 ubiquitin ligase, as well as a linker. It is utilized in the development of PROTAC CDK2/9 Degrader-1[1].

Thalidomide-NH-C6-NH2 TFA is a synthetic conjugate compound that combines a cereblon ligand based on Thalidomide with a linker used in PROTAC technology, functioning as an E3 ligase ligand-linker conjugate[1].

(d(CH2)5[Tyr(Me)2, Dab5]AVP), a vasopressin V1a receptor-specific antagonist, demonstrates a pA2 value of 6.71 [1].

Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based compound designed to degrade CBP and p300, acting as a functional antagonist (WO2020173440).

Thalidomide-5-COOH is a useful organic compound for research related to life sciences. The catalog number is T64600 and the CAS number is 1216805-11-6.

Metal complex, bioreagent

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthetic conjugate compound that combines a Thalidomide-based cereblon ligand and a linker, which is commonly utilized in PROTAC technology. This compound acts as a connector between the target protein and the E3 ligase, facilitating targeted protein degradation.

Thalidomide-NH-PEG2-COOH is a conjugate, synthesized as an E3 ligase ligand-linker, that incorporates the cereblon ligand derived from Thalidomide along with a linker commonly employed in PROTAC technology.

Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc is a synthesized conjugate that functions as an E3 ligase ligand-linker. It includes the cereblon ligand derived from Thalidomide and a linker. This compound, Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc, is employed in the synthesis of PROTAC BET degraders.

Thalidomide-O-C4-COOH is a synthetic conjugate compound, serving as an E3 ligase ligand-linker, which combines a cereblon ligand derived from Thalidomide and a linker utilized in PROTAC technology.

Fmoc-Gly-NH-CH2-acetyloxy serves as a cleavable linker for the synthesis of antibody-drug conjugates (ADCs).

Thalidomide-NH-C9-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein. This compound can be conjugated to a protein-targeting ligand via a linker, enabling the formation of proteolysis-targeting chimeras (PROTACs) [1].